Related Experiment Videos
Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology
1Johns Hopkins Oncology Center, Brady Urological Institute, NIH SPORE in Prostate Cancer, Baltimore, MD 21287, USA.
Abstract:
Whether the current generation of cytokine gene-transduced tumor vaccines will show clinical efficacy is under study. Fortunately, the large safety profile so far observed with gene-transduced tumor vaccines can allow outpatient testing in large populations of patients in the adjuvant therapy situation. This will allow large studies statistically powered to see potentially important adjuvant therapy effects in the range that are observed for tamoxifen in breast cancer. For example, the outpatient, adjuvant therapy safety context has been established in the use of GM-CSF gene-transduced autologous prostate cancer vaccines following radical prostatectomy. Similar adjuvant therapy clinical trial efforts are anticipated with allogeneic breast, colon, pancreatic, and ovarian cancer in addition to prostate, renal cell carcinoma, and melanoma. The reverse translation of early clinical data back to basic laboratory research also suggests the field of cytokine gene-transduced tumor vaccine research will remain vibrant. Efforts are currently being directed on optimizing DC activation with polycistronic constructs of cytokine genes, and overexpressing the most relevant tumor-associated peptides. As in the case of antineoplastic drug development, not all lead compounds will become approved drugs in medical oncology. Rigorous yet innovative clinical trial designs will be key to the accelerated identification of cytokine gene-transduced vaccines that improve survival in cancer patients.
Insights
Cytokine gene-transduced tumor vaccines show a favorable safety profile, enabling outpatient adjuvant therapy trials. These studies aim to identify effective cancer vaccines, similar to tamoxifen
Area of Science:
- Oncology
- Immunology
- Gene Therapy
Background:
- Current cytokine gene-transduced tumor vaccines are under investigation for clinical efficacy.
- Gene-transduced tumor vaccines have demonstrated a large safety profile, allowing for outpatient testing.
- The adjuvant therapy setting is suitable for large, statistically powered studies of these vaccines.
Purpose of the Study:
- To evaluate the clinical efficacy of cytokine gene-transduced tumor vaccines in various cancers.
- To establish the safety context for outpatient adjuvant therapy using these vaccines.
- To explore the potential for adjuvant therapy effects comparable to tamoxifen in breast cancer.
Main Methods:
- Outpatient testing in large patient populations for adjuvant therapy.
- Clinical trials involving GM-CSF gene-transduced autologous prostate cancer vaccines post-prostatectomy.
- Anticipated trials for allogeneic breast, colon, pancreatic, ovarian, prostate, renal cell carcinoma, and melanoma.
Main Results:
- Established safety context for GM-CSF gene-transduced autologous prostate cancer vaccines in adjuvant therapy.
- Potential for statistically powered studies to detect adjuvant therapy effects.
- Vibrant research field suggested by reverse translation of early clinical data.
Conclusions:
- Cytokine gene-transduced tumor vaccines hold promise for cancer treatment, particularly in the adjuvant setting.
- Optimizing DC activation and peptide overexpression are key research directions.
- Innovative clinical trial designs are crucial for identifying survival-improving vaccines.